About the Company
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CALA News
Calithera Biosciences, Inc. (CALA)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
MILLENNIUM PHARMACEUTICALS INC's Net Worth
MILLENNIUM PHARMACEUTICALS INC has an estimated net worth of $119 Million. This is based on reported shares across multiple companies, which include Calithera Biosciences, Inc., Day One ...
Pacira BioSciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Calithera to Present at the 2021 Jefferies London Healthcare Conference
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company ...
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript February 29, 2024 Pacira BioSciences, Inc. reports earnings inline with expectations. Reported EPS is $0.89 EPS ...
Aptose Biosciences Inc APTO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Forte Biosciences Inc.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...
Calithera Biosciences Inc (CALA)
Calithera Biosciences, Inc. (NASDAQ:CALA) initiated a phase I/II open-label study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer’s ...
Calithera Biosciences Inc CALA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Calithera Biosciences Inc (CALA)
Calithera Biosciences, Inc. (NASDAQ:CALA) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock ...
CALA Calithera Biosciences, Inc.
The security has traded for less than one year There is no Wall Street analyst coverage The security is a closed-end fund or a mortgage REIT The security is listed on a non-US exchange The ...
Calithera Biosciences, Inc. (CALA)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...